@Gsinc It looks like you’re new here, so I’d suggest taking some time to go through our past announcements and check out some old interviews. They’re helpful in getting a feel for shareholder expectations, which were set by the company. That way, you can also understand where any 'negativity' stems from.
Example
https://hotcopper.com.au/documentembed?id=sC1D18q3MHQ4ga8wwAQ7OFUjQihe7Ga8swYV3svdfo5eXMBP0Jv0aGOhDdW0Kubo
4DMedical receives commitments for A$40.0 million via a Placement at A$1.55 per share
• Proceeds from the Placement will primarily fund, in conjunction with the $28.9m of MRFF funding,
the development and commercialisation of the world’s first dedicated lung function scanner – XVD
Scanner™. It was a commitment of the grant bid to the MRFF that 4DMedical provide new capital
for the development of the XVD Scanner
“4DMedical will have full commercialisation rights for XVD Scanners and lead sales and marketing for these products. The Company expects to start commercialising the Generation One XVD Scanner in 2023, two years before the Generation Two version which is expected to be commercialised in 2025."
(20min delay)